These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 21063910

  • 1. Two BRCA1/2 founder mutations in Jews of Sephardic origin.
    Sagi M, Eilat A, Ben Avi L, Goldberg Y, Bercovich D, Hamburger T, Peretz T, Lerer I.
    Fam Cancer; 2011 Mar; 10(1):59-63. PubMed ID: 21063910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC.
    JAMA Oncol; 2017 Dec 01; 3(12):1647-1653. PubMed ID: 28727877
    [Abstract] [Full Text] [Related]

  • 4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 01; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 5. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D.
    Am J Hum Genet; 1997 May 01; 60(5):1059-67. PubMed ID: 9150153
    [Abstract] [Full Text] [Related]

  • 6. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.
    Am J Hum Genet; 1997 Mar 01; 60(3):505-14. PubMed ID: 9042909
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA.
    Am J Hum Genet; 1999 Apr 01; 64(4):963-70. PubMed ID: 10090881
    [Abstract] [Full Text] [Related]

  • 11. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E.
    Breast Cancer Res Treat; 2011 Sep 01; 129(2):557-63. PubMed ID: 21499684
    [Abstract] [Full Text] [Related]

  • 12. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y.
    Breast Cancer Res Treat; 2018 Nov 01; 172(1):151-157. PubMed ID: 30014164
    [Abstract] [Full Text] [Related]

  • 13. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
    Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B, Zidan J, Friedman E.
    Breast Cancer Res Treat; 2012 Jun 01; 133(3):1153-7. PubMed ID: 22399190
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK, Kopparam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, Caputo T, Holcomb K, Chapman-Davis E.
    Cancer; 2019 Mar 01; 125(5):690-697. PubMed ID: 30480775
    [Abstract] [Full Text] [Related]

  • 16. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H.
    Cancer; 2014 Jul 01; 120(13):1960-7. PubMed ID: 24737347
    [Abstract] [Full Text] [Related]

  • 17. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M.
    Breast Cancer Res Treat; 2011 Aug 01; 129(1):185-90. PubMed ID: 21394499
    [Abstract] [Full Text] [Related]

  • 18. The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.
    Quintana-Murci L, Gal I, Bakhan T, Quach H, Sayar SH, Shiri-Sverdlov R, Baruch RG, McElreavey K, Dagan E, Narod S, Friedman E.
    Fam Cancer; 2005 Aug 01; 4(2):85-8. PubMed ID: 15951957
    [Abstract] [Full Text] [Related]

  • 19. The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
    Bernstein-Molho R, Laitman Y, Schayek H, Reish O, Lotan S, Haim S, Zidan J, Friedman E.
    Breast Cancer Res Treat; 2018 Feb 01; 167(3):697-702. PubMed ID: 29086229
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.